Eisai and the UK Dementia Research Institute (UK DRI) announced the launch of a joint postdoctoral program to support the promotion of nuclear research.
The collaboration will bring together the world's best expertise in one national institution that researches all aspects of dementia including Alzheimer's disease, Parkinson's disease, initial dementia, vascular dementia, and Huntington's disease. Under the joint program, postdoctoral researchers engaged in dementia research will be provided with a grant from 2019 to 2023.
The DRI in the UK will contribute to its state-of-the-art research facilities and Eisai will provide its drug discovery and translation expertise, which will support the work of the organization in clarifying novel drug discovery targets and mechanisms, developing novel dementia models, and accelerating the development of new drugs. linking these research findings to diagnostics, treatment and care.
"Eisai is delighted to be able to initiate this joint program with the UK DRI, the world's largest dementia research institute," said Dr Teiji Kimura, chief discovery officer of the Neuroscience Business Group.
He continued, "As the first co-operation program by the UK DRI with a private company, this program is a very unique effort to provide an environment in which postdoctoral researchers engaged in the latest research on dementia in the UK can To show the whole Under this program, we hope to achieve new ideas that can be associated with dementia treatment. "
It is estimated that there are approximately 50 million dementia patients worldwide, and as the global population ages, it is expected that this trend will continue to be seen by the number of dementia patients around the world, and is estimated to have a higher incidence of dementia. the total number of people with dementia will reach 82 million in 2030 and 152 million in 2050.
.Leave a comment